Cerebral Infarction and White Substance in Angiopathy Cerebral Amyloid

NCT03262246 | Completed

• 1 other identifier: ISAAC
• Study Type: observational
• Target: 126
• Locations: 1 country
• Sites: 1

Brief Summary

The cerebral amyloïd angiopathy ( AAC) is a disease characterized by deposits of beta-amyloid peptids in the walls of the arteries of young and average calibre of the brain and the leptomeninx. The incidence of the AAC increases strongly with the age and represents a major cause of spontaneous brain haemorrhage to people over 60. The main demonstration is the lobar brain haemorrhage, the other ones are bleedings under arachnoid cortical and microbleedings leading to cognitive decline. Anatomical studies reported the presence of cortical infarcts in patients having amyloïd deposits suggesting an association between asymptomatic cortical cerebral infarcts and AAC. However prevalence and meaning of these infarcts in patients having an AAC remain badly known because of studies on low number of patients and the rarity of radiological analyses of these infarcts .A better knowledge of these asymptomatic cortical infarcts would allow to dread better cognitive disorders(confusions) presented by these patients, and to develop preventive strategies. Besides, the risk factors of severity of the AAC are little studied.

Conditions

Amyloid Angiopathy

Outcome Measures

Primary Outcomes (1)

• number of patient with cerebral infarction and associated factors in a cohort of cerebral amyloid angiopathy patients

  1day

Interventions

medical report consultation OTHER

investigators consult medical report concerning patient identified for cerebral amyloid angiopathy

Eligibility Criteria

• Age: 55 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Investigators select medical report of hospitalized patient between 2011/01/01 and 2015/12/31 in CAEN hospital and Paris St Joseph hospital ; these had an MRI for cerebral haemorrhage.

You may qualify if:

• age\>55
• hospitalized in CAEN hospital and Paris St Joseph Hospital between 1st january 2011 and 31 december 2015 for cerebral haemorrhage with MRI images diagnosing cerebral amyloid angiopathy.

You may not qualify if:

• Insufficient MRI images quality without FLAI sequence, T2 GRE
• disease with same radiologic and clinical signs that cerebral amyloid angiopathy.

Sponsors & Collaborators

• Fondation Hôpital Saint-Joseph: lead

Study Sites (1)

Groupe Hospitalier Paris Saint Joseph

Paris, Île-de-France Region, 75014, France

Location

MeSH Terms

Conditions

Amyloid angiopathy

Study Officials

• HODEL Jérome, Professor

  GHPSJ

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 24, 2017
• First Posted: August 25, 2017
• Study Start: June 2, 2016
• Primary Completion: December 31, 2016
• Study Completion: December 31, 2018
• Last Updated: February 4, 2019

Record last verified: 2018-08

Locations

FR (1)